Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 16/20 | 0.97 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.56 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.56 |
| ▸ | F2 | P00734 | 1/20 | 0.56 |
| ▸ | ST14 | Q9Y5Y6 | 1/20 | 0.56 |
| ▸ | CYP2J2 | P51589 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL792571 | 1.00 | F10 (0.97) | F10CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL15203246 | 0.99 | F10 (1.00) | F10CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL87178 | 0.99 | F10 (1.00) | F10CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL455793 | 0.99 | F10 (1.00) | F10CYP1A2CYP3A4CYP2D6CYP2C9 | |
| Sulfuric Acid SCHEMBL793039 | 0.93 | F10 (0.88) | F10CYP1A2CYP3A4CYP2D6CYP2C9 | |
| Sulfuric Acid SCHEMBL793040 | 0.93 | F10 (0.88) | F10CYP1A2CYP3A4CYP2D6CYP2C9 | |
| Oxalic Acid SCHEMBL14861652 | 0.93 | F10 (0.88) | F10CYP1A2CYP3A4CYP2D6CYP2C9 | |
| Acetic Acid SCHEMBL13736179 | 0.92 | F10 (0.86) | F10CYP1A2CYP3A4CYP2D6CYP2C9 | |
| Acetic Acid SCHEMBL13737134 | 0.92 | F10 (0.86) | F10CYP1A2CYP3A4CYP2D6CYP2C9 | |
| Acetic Acid SCHEMBL13738152 | 0.92 | F10 (0.86) | F10CYP1A2CYP3A4CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115536651-B | Rivaroxad method for preparing class | 陕西汉江药业集团股份有限公司 | 2025-03-18 | — | — | CN | claimed |
| CN-115490678-B | Preparation method of high-purity rivaroxaban | 浙江苏泊尔制药有限公司 | 2025-02-18 | — | — | CN | claimed |
| CN-115490678-A | Preparation method of high-purity rivaroxaban | 浙江苏泊尔制药有限公司 | 2022-12-20 | — | — | CN | claimed |
| CN-115215854-A | Preparation process of efficient rivaroxaban bulk drug | 湖南恒生制药股份有限公司 | 2022-10-21 | — | — | CN | claimed |
| CN-114685480-A | Method for refining and crushing rivaroxaban bulk drug | 江苏嘉逸医药有限公司 | 2022-07-01 | — | — | CN | claimed |
| US-20110288294-A1 | Preparation process for an inhibitor of a blood clotting factor | ARCHIMICA GMBH (DE) | 2011-11-24 | — | — | US | claimed |
| US-7351823-B2 | Preparation process | BAYER HEALTHCARE AG (DE) | 2008-04-01 | — | — | US | claimed |
| US-20050182055-A1 | 5-Chloro-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)phenyl]-1,3-oxazolidin-5-yl}methyl)-2-thiophenecarboxamide formed by reacting 4-{4-[(5S)-5-(aminomethyl)-2-oxo-1,3-oxazolidin-3-yl]phenyl}-morpholin-3-one hydrochloride with 5-chlorothiophene-2-carbonyl chloride | BAYER HEALTHCARE AG (DE) | 2005-08-18 | — | — | US | claimed |
| CN-115536651-B | Rivaroxad method for preparing class | 陕西汉江药业集团股份有限公司 | 2025-03-18 | — | — | CN | disclosed |
| CN-115490678-B | Preparation method of high-purity rivaroxaban | 浙江苏泊尔制药有限公司 | 2025-02-18 | — | — | CN | disclosed |
| CN-115745984-B | Rivaroxaban easy to crush and preparation method thereof | 北京四环制药有限公司 | 2024-11-29 | — | — | CN | disclosed |
| CN-110003193-B | Rivaroxaban easy to crush and preparation method thereof | 北京四环制药有限公司 | 2023-12-05 | — | — | CN | disclosed |
| CN-111699184-B | Process for producing oxazolidinone compound | 住友化学株式会社 | 2023-05-23 | — | — | CN | disclosed |
| CN-115745984-A | Rivaroxaban easy to crush and preparation method thereof | 北京四环制药有限公司 | 2023-03-07 | — | — | CN | disclosed |
| EP-2616466-A2 | PROCESS FOR DETERMINING THE SUITABILITY FOR DISTRIBUTION OF A BATCH OF A THIOPHENE-2-CARBOXAMIDE DERIVATIVE | Medichem, S.A. (ES) | 2013-07-24 | — | — | EP | disclosed |
| WO-2012153155-A1 | PROCESS FOR THE PREPARATION OF A RIVAROXABAN AND INTERMEDIATES FORMED IN SAID PROCESS | EGIS GYÓGYSZERGYÁR NYILVÃNOSAN MÜKÖDÖ RÉSZVÉNY-TÁRSASÁG (HU) | 2012-11-15 | — | — | WO | disclosed |
| WO-2012140061-A1 | METHOD FOR THE PREPARATION OF SUBSTITUTED OXAZOLIDINONES | SANDOZ AG (CH) | 2012-10-18 | — | — | WO | disclosed |
| WO-2012035057-A2 | PROCESS FOR DETERMINING THE SUITABILITY FOR DISTRIBUTION OF A BATCH OF A THIOPHENE-2-CARBOXAMIDE DERIVATIVE | MEDICHEM S.A. (ES) | 2012-03-22 | — | — | WO | disclosed |
| CN-102311400-A | Process for the preparation of 5-L-aminomethyl-3-aryl-2-oxazolidone | XIANGZHEN BIOTECHNOLOGY CO LTD | 2012-01-11 | — | — | CN | disclosed |
| US-20110288294-A1 | Preparation process for an inhibitor of a blood clotting factor | ARCHIMICA GMBH (DE) | 2011-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110288294-A1 | Preparation process for an inhibitor of a blood clotting factor | TFPI, F5, F11 | F10 10/4885CYP1A2 972/4885CYP3A4 484/4885 |
| US-20050182055-A1 | 5-Chloro-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)phenyl]-1,3-oxazolidin-5-yl}methyl)-2-thiophenecarboxamide formed by reacting 4-{4-[(5S)-5-(aminomethyl)-2-oxo-1,3-oxazolidin-3-yl]phenyl}-morpholin-3-one hydrochloride with 5-chlorothiophene-2-carbonyl chloride | NT5C, HTR2C, HTR5A | F10 4646/4885CYP1A2 908/4885CYP3A4 962/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.